Document is current
Any future updates will be listed below
-
Authors
Sadda, Srinivas https://orcid.org/0000-0002-4939-3306
Hatcher, Kensington A.
Shah, Birva K.
Kondapalli, Srinivas Sai
Li, Chao
Baumal, Caroline R.
-
Funding
Funding for this research was provided by:
Apellis Pharmaceuticals
- License Information
-
More Information
Article History
Received: 19 December 2024
Accepted: 23 April 2025
First Online: 19 May 2025
Declarations
:
: Srinivas Sadda has received consulting fees from Apellis, Amgen, AbbVie/Allergan, Alexion, Samsung Bioepis, Biogen, Boehringer Ingelheim, Iveric Bio, Novartis, Roche, Bayer, Regeneron, Pfizer, Astellas, Nanoscope, Janssen, ssCenterVue, Optos, Heidelberg Notal Vision, Eyepoint, Character, and OTx and honoraria from Novartis, Roche, Optos, and Heidelberg. Chao Li and Caroline R. Baumal are employees of Apellis and may hold stock or stock options. Birva K. Shah and Kensington A. Hatcher are former employees of Apellis and may hold stock or stock options. Srinivas Sai Kondapalli has received speaker honoraria from Regeneron and is an owner of Rinsada.
: As this was a retrospective analysis, institutional review board approval was not required. For the OAKS and DERBY studies, study protocols were approved by institutional review boards or ethics committees at each site. Both studies adhered to the Declaration of Helsinki. All patients who participated in the OAKS and DERBY studies provided written informed consent.
